Syndax Total Debt To Capitalization from 2010 to 2025

SNDX Stock  USD 13.08  0.08  0.62%   
Syndax Pharmaceuticals Total Debt To Capitalization yearly trend continues to be fairly stable with very little volatility. Total Debt To Capitalization will likely drop to 0 in 2025. During the period from 2010 to 2025, Syndax Pharmaceuticals Total Debt To Capitalization regression line of annual values had significance of  0.02 and arithmetic mean of  8.49. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.003383
Current Value
0.003214
Quarterly Volatility
23.01399574
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Syndax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syndax Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.1 K, Interest Expense of 227.2 K or Selling General Administrative of 65.6 M, as well as many indicators such as Price To Sales Ratio of 6.97, Dividend Yield of 0.0198 or PTB Ratio of 2.59. Syndax financial statements analysis is a perfect complement when working with Syndax Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Syndax Pharmaceuticals Correlation against competitors.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Latest Syndax Pharmaceuticals' Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of Syndax Pharmaceuticals over the last few years. It is Syndax Pharmaceuticals' Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syndax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Slightly volatile
   Total Debt To Capitalization   
       Timeline  

Syndax Total Debt To Capitalization Regression Statistics

Arithmetic Mean8.49
Coefficient Of Variation271.20
Mean Deviation14.73
Median0.03
Standard Deviation23.01
Sample Variance529.64
Range70.0801
R-Value(0.57)
Mean Square Error381.07
R-Squared0.33
Significance0.02
Slope(2.77)
Total Sum of Squares7,945

Syndax Total Debt To Capitalization History

2025 0.003214
2024 0.003383
2023 0.002942
2022 0.002478
2021 0.0488
2020 0.0753

About Syndax Pharmaceuticals Financial Statements

Syndax Pharmaceuticals investors use historical fundamental indicators, such as Syndax Pharmaceuticals' Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Syndax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.